In the past, few pharmacologic agents were available for management of fungal disease. After the early introduction of amphotericin B and miconazole, the more recent advent of several new antifungal agents, including ketoconazole, fluconazole, and itraconazole has expanded the options for treatment of fungal infections. The dramatic increase in number of immunocompromised patients-both those with acquired immunodeficiency syndrome (AIDS) and those with immunosuppression for other reasons, such as organ transplantation-emphasizes the importance of therapeutic strategies for combating systemic mycoses. In this article, we review our personal recommendations for treating histoplasmosis, blastomycosis, coccidioidomycosis, and cryptococcosis, along with other less common fungal infections, and discuss the efficacy and toxic effects of the various antifungal drugs.
机构:
UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED, DIV INFECT DIS,ROOM B-226, LOS ANGELES, CA 90048 USAUNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED, DIV INFECT DIS,ROOM B-226, LOS ANGELES, CA 90048 USA
DAAR, ES
MEYER, RD
论文数: 0引用数: 0
h-index: 0
机构:
UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED, DIV INFECT DIS,ROOM B-226, LOS ANGELES, CA 90048 USAUNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,DEPT MED, DIV INFECT DIS,ROOM B-226, LOS ANGELES, CA 90048 USA